{"nctId":"NCT01465178","briefTitle":"Improving the Understanding of the Response to Vitamin D Supplementation","startDateStruct":{"date":"2011-12"},"conditions":["Vitamin D Deficiency"],"count":62,"armGroups":[{"label":"2000 IU vitamin D3","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: cholecalciferol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: Placebo"]}],"interventions":[{"name":"cholecalciferol","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy, community-dwelling ambulatory postmenopausal White, non-Hispanic women\n* Able and willing to sign informed consent\n* Baseline serum 25(OH)D concentration of 10-29 ng/mL\n* Willing to not alter the amount of their baseline vitamin D supplementation during the course of this study\n* Willing to use sunscreen (SPF ≥15) when sun exposure of \\> 15 minutes is expected\n\nExclusion Criteria:\n\n* Presence of any measurable circulating 25(OH)D2 on screening measurement\n* Current hypercalcemia (serum calcium \\> 10.5 mg/dl) or untreated primary hyperparathyroidism\n* History of nephrolithiasis\n* Known risk factors for hypercalcemia, e.g., malignancy, tuberculosis, sarcoidosis\n* History of any form of cancer within the past five years with the exception of adequately treated squamous cell or basal cell skin carcinoma\n* Renal failure; defined as a calculated creatinine clearance (using the Cockroft-Gault approach) of ≤ 35 ml/minute\n* Severe end-organ disease, e.g., cardiovascular, hepatic, hematologic, pulmonary, etc., which might limit the ability to complete this study\n* Known metabolic bone disease, e.g., Paget's disease, osteomalacia\n* Treatment with any drug known to interfere with vitamin D metabolism, e.g., phenytoin, phenobarbital\n* Treatment with high dose vitamin D (≥ 50,000 IU weekly) or any active metabolites of vitamin D, e.g., calcitriol, within six months of screening\n* Use of tanning beds or salons or unwillingness to utilize sunscreen during periods of sun exposure of 15 minutes or longer\n* Planned trips/vacations likely to be associated with substantial amounts of sun exposure during the course of the study","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"50 Years","maximumAge":"100 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Serum 25-hydroxy Vitamin D3","description":"Our primary outcome variable is the effect of supplementation on change in serum 25(OH)D3;","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"4.1"},{"groupId":"OG001","value":"-0.8","spread":"4.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"5.8"},{"groupId":"OG001","value":"0.3","spread":"4.1"}]}]}]},{"type":"SECONDARY","title":"Change in Parameters of the Vitamin D Assay Panel","description":"Secondary outcomes are change in cholecalciferol, 24,25(OH)D3 and free 25(OH)D3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"4.3"},{"groupId":"OG001","value":"-0.6","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"5.7"},{"groupId":"OG001","value":"-0.20","spread":"2.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":".08"},{"groupId":"OG001","value":"-0.2","spread":"0.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.91"},{"groupId":"OG001","value":"-0.1","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.3"},{"groupId":"OG001","value":"-0.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.9"},{"groupId":"OG001","value":"-0.1","spread":"1.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["diarrhea","Depression"]}}}